Bristol-Myers won't seek accelerated Opdivo lung cancer approval

Jan 19 (Reuters) - Bristol-Myers Squibb Co on

Thursday said it has decided not to seek accelerated U.S.

approval for its combination of two immunotherapy drugs as an

initial treatment for lung cancer.

Read more